<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Radiology Product Guide &#187; Modulating Apoptosis</title>
	<atom:link href="http://www.radiologyproductguide.com/blog/tag/modulating-apoptosis/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.radiologyproductguide.com/blog</link>
	<description>A comprehensive guide to radiology products for radiologists and other medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:58:13 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Cleveland BioLabs Receives First U.S. Patent For Radiation Protection Drug CBLB502</title>
		<link>http://www.radiologyproductguide.com/blog/2010/01/08/cleveland-biolabs-receives-first-u-s-patent-for-radiation-protection-drug-cblb502/</link>
		<comments>http://www.radiologyproductguide.com/blog/2010/01/08/cleveland-biolabs-receives-first-u-s-patent-for-radiation-protection-drug-cblb502/#comments</comments>
		<pubDate>Fri, 08 Jan 2010 13:38:40 +0000</pubDate>
		<dc:creator>Matt Littlefield</dc:creator>
				<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Radiation Therapy]]></category>
		<category><![CDATA[Cleveland BioLabs]]></category>
		<category><![CDATA[Eurasian Patent Organization]]></category>
		<category><![CDATA[Modulating Apoptosis]]></category>
		<category><![CDATA[U.S. Patent and Trademark Office]]></category>

		<guid isPermaLink="false">http://www.radiologyproductguide.com/blog/?p=174</guid>
		<description><![CDATA[Cleveland BioLabs, Inc. announced that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled &#8220;Modulating Apoptosis&#8221; covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.radiologyproductguide.com/blog/wp-content/uploads/2010/01/Cleveland-BioLabs.png"><img class="alignleft size-full wp-image-175" style="margin: 5px" src="http://www.radiologyproductguide.com/blog/wp-content/uploads/2010/01/Cleveland-BioLabs.png" border="0" alt="Cleveland BioLabs" width="200" height="53" /></a>Cleveland BioLabs, Inc. announced that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled &#8220;Modulating Apoptosis&#8221; covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations. Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the U.S.</p>
<p>For the full story, <a href="http://www.medicalnewstoday.com/articles/175360.php" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.radiologyproductguide.com/blog/2010/01/08/cleveland-biolabs-receives-first-u-s-patent-for-radiation-protection-drug-cblb502/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
